Advertisement

Obesity Surgery

, Volume 19, Issue 8, pp 1084–1088 | Cite as

Improvement of Metabolic Syndrome Following Intragastric Balloon: 1 Year Follow-up Analysis

  • Nicola CreaEmail author
  • Giacomo Pata
  • Domenico Della Casa
  • Luigi Minelli
  • Giovanni Maifredi
  • Ernesto Di Betta
  • Francesco Mittempergher
Clinical Report

Abstract

Objective

This study aimed to assess the impact of intragastric balloon (IGB)-induced body weight loss on metabolic syndrome in obese patients and evaluate what happens during 1-year follow-up.

Methods

To this end, data were collected on 143 obese patients (body mass index (BMI) 36.2 ± 5.7 kg/m²) who underwent IGB insertion between January 2000 and December 2005. Outcomes were recorded at BioEnterics Intragastric Balloon removal time (t0) and at 6-month (t6) and 12-month (t12) follow-up.

Results

Significant BMI, excess body weight loss percentage, and body weight loss percentage (BWL%) were observed at t0 (29.6 ± 4.6 kg/m²; 29.3 ± 4.8%; 14.1 ± 5.7%), followed by partial weight regain at t12 (32.4 ± 4.3 kg/m²; 26.1 ± 4.9%; 11.2 ± 4.6%). Incidence of metabolic syndrome dropped from 34.8% (pre-IGB value) to 14.5% (t0) and 11.6% (t12). Likewise, type 2 diabetes mellitus (DM), hypertriglyceridemia, hypercholesterolemia, and blood hypertension (BH) incidence decreased from 32.6%, 37.7%, 33.4%, and 44.9% (pre-IGB values) to 20.9%, 14.5%, 16.7%, and 30.4% at t0 and 21.3%, 17.4%, 18.9%, and 34.8% at t12. HbA1c blood concentration shifted from an initial value of 7.5 ± 2.1% to 5.7 ± 1.9% (t0), 5.6 ± 0.7% (t6), and 5.5 ± 0.9% (t12). Patients suffering from DM or BH stopped or diminished relative drug consumption at t12. Negligible modifications were reported as regards HDL cholesterol and hyperuricemia.

Conclusion

Weight regain is commonly observed during long-term follow-up after IGB removal. Nevertheless, the maintenance of at least 10% of the BWL%, as reported at 1-year follow-up, is associated with an improvement in metabolic syndrome.

Keywords

Intragastric balloon Obesity Metabolic syndrome 

References

  1. 1.
    Loffredo A, Cappuccio M, De Luca M, et al. Three years experience with the new intragastric balloon, and a preoperative test for success with restrictive surgery. Obes Surg. 2001;11:330–3.CrossRefGoogle Scholar
  2. 2.
    Roman S, Napoleon B, Mion F, et al. Intragastric balloon for “non-morbid” obesity: a retrospective evaluation of tolerance and efficacy. Obes Surg. 2004;14:539–44.CrossRefGoogle Scholar
  3. 3.
    Doldi SB, Micheletto G, Perrini MN, et al. Treatment of morbid obesity with intragastric balloon in association with diet. Obes Surg. 2002;12:583–92.CrossRefGoogle Scholar
  4. 4.
    De Waele B, Reynaert H, Urbain D, et al. Intragastric balloons for preoperative weight reduction. Obes Surg. 2000;10:58–60.CrossRefGoogle Scholar
  5. 5.
    Wahlen CH, Bastens B, Herve J, et al. The BioEnterics Intragastric Balloon (BIB): how to use it. Obes Surg. 2001;11:524–7.CrossRefGoogle Scholar
  6. 6.
    Spyropoulos C, Katsakoulis E, Mead N, et al. Intragastric balloon for high-risk super-obese patients: a prospective analysis of efficacy. Surg Obes Relat Dis. 2007;3:78–83.CrossRefGoogle Scholar
  7. 7.
    Sallet JA, Marchesini JB, Pavia DS, et al. Brazilian multi center study of intragastric balloon. Obes Surg. 2004;14:991–8.CrossRefGoogle Scholar
  8. 8.
    Imaz I, Martinez-Cervell C, Garcia-Alvarez EE, et al. Safety and effectiveness of the intragastric balloon for obesity. A meta-analysis. Obes Surg. 2008;18:841–6.CrossRefGoogle Scholar
  9. 9.
    Mittempergher F, Di Betta E, Pata G, et al. The obstructive sleep apnea in bariatric surgery. Ann Ital Chir. 2008;79:165–70.PubMedGoogle Scholar
  10. 10.
    Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15:539–53.CrossRefGoogle Scholar
  11. 11.
    Strazzullo P, Barbato A, Siani A, et al. Diagnostic criteria for metabolic syndrome: a comparative analysis in an unselected sample of adult male population. Metabolism. 2008;57:355–61.CrossRefGoogle Scholar
  12. 12.
    Pischon T, Boeing H, Hoffmann K, et al. General and abdominal adiposity and risk of death in Europe. N Engl J Med. 2008;359:2105–20.CrossRefGoogle Scholar
  13. 13.
    Ammar KA, Redfield MM, Mahoney DW, et al. Central obesity: association with left ventricular dysfunction and mortality in the community. Am Heart J. 2008;156:975–81.CrossRefGoogle Scholar
  14. 14.
    Shimabukuro M. Cardiac adiposity and global cardiometabolic risk: new concept and clinical intervention. Circ J. 2008;73:27–34.CrossRefGoogle Scholar
  15. 15.
    Artham SM, Lavie CJ, Patel HM. Impact of obesity on the risk of heart failure and its prognosis. J Cardiometab Syndr. 2008;3:155–61.CrossRefGoogle Scholar
  16. 16.
    Franz MJ, VanWormer JJ, Crain AL, et al. Weight-loss outcomes: a systematic review and meta-analysis of weight-loss clinical trials with a minimum 1-year follow-up. J Am Diet Assoc. 2007;107:1755–67.CrossRefGoogle Scholar
  17. 17.
    Avenell A, Brown TJ, McGee MA, et al. What interventions should we add to weight reducing diets in adults with obesity? A systematic review of randomized controlled trials of adding drug therapy, exercise, behaviour therapy or combinations of these interventions. J Hum Nutr Diet. 2004;17:293–316.CrossRefGoogle Scholar
  18. 18.
    Curioni CC, Lourenço PM. Long-term weight loss after diet and exercise: a systematic review. Int J Obes (Lond). 2005;29:1168–74.CrossRefGoogle Scholar
  19. 19.
    Herve J, Wahlen H, Schaeken A, et al. What becomes of patients one year after the intragastric balloon has been removed? Obes Surg. 2005;15:864–70.CrossRefGoogle Scholar
  20. 20.
    Angrisani L, Lorenzo M, Borrelli V, et al. Is bariatric surgery necessary after intragastric balloon treatment? Obes Surg. 2006;16:1135–7.CrossRefGoogle Scholar
  21. 21.
    Mathus-Vliegen EM, Tytgat GN. Intragastric balloon for treatment-resistant obesity: safety, tolerance, and efficacy of 1-year balloon treatment followed by a 1-year balloon free follow-up. Gastrointest Endosc. 2005;61:19–27.CrossRefGoogle Scholar
  22. 22.
    Genco A, Bruni T, Doldi SB, et al. BioEnterics intragastric Balloon: the Italian Experience with 2.515 patients. Obes Surg. 2005;15:1161–4.CrossRefGoogle Scholar
  23. 23.
    Mui WL, Ng EK, Tsung BY et al. Impact on obesity-related illnesses and quality of life following intragastric balloon. Obes Surg. 2008; (in press).Google Scholar
  24. 24.
    Ricci G, Bersani G, Rossi A, et al. Bariatric therapy with intragastric balloon improves liver dysfunction and insulin resistance in obese patients. Obes Surg. 2008;18:1438–42.CrossRefGoogle Scholar
  25. 25.
    Deitel M. How much weight loss is sufficient to overcome major co-morbidities? Obes Surg. 2001;11:659.CrossRefGoogle Scholar

Copyright information

© Springer Science + Business Media, LLC 2009

Authors and Affiliations

  • Nicola Crea
    • 1
    Email author
  • Giacomo Pata
    • 1
  • Domenico Della Casa
    • 2
  • Luigi Minelli
    • 2
  • Giovanni Maifredi
    • 3
  • Ernesto Di Betta
    • 1
  • Francesco Mittempergher
    • 1
  1. 1.Department of Medical and Surgical Sciences, General SurgeryUniversity of BresciaBresciaItaly
  2. 2.Department of Medical and Surgical Sciences, Surgical EndoscopyUniversity of BresciaBresciaItaly
  3. 3.Department of Experimental and Applied Medicine, Institute of Hygiene, Epidemiology and Public HealthUniversity of BresciaBresciaItaly

Personalised recommendations